Ahmedabad-based pharma major, Zydus Cadila, has recieved an approval from the Drug Controller General of India (DCGI) to market H1N1 (swine flu) vaccines in the country. The vaccine will be marketed under the brand name VaxiFlu-S.
"With this, the company will become the first Indian pharma company to launch the vaccine," the company said in a release.
VaxiFlu-S will be marketed by Vaxxicare, a division of the group that focuses on preventives. The company has also set up a dedicated taskforce to market the vaccine.
"With the vaccine in the market soon, we would be better prepared with an affordable therapy and prevent further loss of lives to this infectious disease. The launch of VaxiFlu-S gives added thrust to our objective of emerging as a strong player in the area of preventives," said Pankaj R Patel, chairman and managing director, Zydus Cadila.
The egg-based, inactivated vaccine based on conventional technology has been developed by the group's researchers at its Vaccine Technology Centre (VTC) in Ahmedabad.
VTC further plans to develop a wide spectrum of vaccines against bacterial, viral and protozoal infections.
